GSK (GSK plc) צמיחה צפויה ברווח נקי למניה השנה

Geopolitical risks and supply chain disruptions from Asia are creating volatility, as evidenced by the 12-month relative EPS growth rate, where the current metric stands at 1.70. GSK plc (GSK) maintains stability through its manufacturing plants in the US and UK, while its dominance in the vaccines and HIV therapy segments helps sustain high margins, successfully countering market pressure.

This metric measures the annual growth rate of net income per share, reflecting the business's ability to generate value amid rising costs. This historical trend of annual net income per share allows for an assessment of the R&D strategy efficiency at GSK plc (GSK) and the success of the management transformation following the Haleon spin-off, confirming management's ability to offset the loss of patent protection with real growth in profitability.